
Researchers hope to learn more about the safety of celecoxib from a clinical trial being conducted by researchers at the Cleveland Clinic, who are testing the drug against ibuprofen and naproxen in some 20,000 patients who have or are at high risk of heart disease. Results are expected in several years.
In the meantime, we continue to believe that celecoxib should be used as a last resort, and only by people who are at low risk of heart disease or stroke, high risk of gastrointestinal problems, or who have not responded to less risky alternatives. Patients who have diabetes, heart disease, elevated cholesterol levels, or high blood pressure should be especially cautious about using the drug.
Consumer Reports medical advisers recommend the following drugs for:
Most people with osteoarthritis: Generic acetaminophen. When used at recommended doses it is generally the safest drug and often provides adequate relief.
People who don't get adequate relief from acetaminophen or can't take it for health reasons: Generic ibuprofen or naproxen. Those drugs are cheaper than other NSAIDs, and less likely than aspirin to harm the stomach.
People at high risk of heart attack: Naproxen. While aspirin is also safe for the heart, the doses needed to control pain pose unacceptable risks to the stomach.
People at high risk of gastrointestinal bleeding: Combine ibuprofen or naproxen with a stomach-protecting drug such as omeprazole (Prilosec and generic), or possibly consider celecoxib if you're also at low risk of heart disease.
Regardless of which drug you opt for, use the lowest effective dose for the shortest period of time possible. In addition,
take these other steps to reduce the risks or your need for drugs:
This drug safety alert is made possible through a partnership between Consumer Reports Best Buy Drugs and the Research on Adverse Drug Events and Reports (RADAR) group, a pharmacovigilance group led by Charles Bennett, M.D. Ph.D. M.P.P. This is the third in a series of reports based on research by the RADAR group.
These materials are made possible by a grant from the state Attorney General Consumer and Prescriber Education Grant Program, which is funded by the multi-state settlement of consumer-fraud claims regarding the marketing of the prescription drug Neurontin (gabapentin).
If you think you have experienced an adverse event with this drug or any drug, especially if it is of a serious nature, it is important to 1) tell your doctor immediately and 2) report the event to the Food and Drug Administration via the FDA's MedWatch Web site at https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm or by calling 1-800-FDA-1088.